Michael Levitz
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Michael Levitz
Michael Levitz is recorded as CFO at Anika Therapeutics, Inc. (ANIK). Anika Therapeutics, Inc. reported in an 8-K filed May 8, 2024 that Michael Levitz resigned as Chief Financial Officer, effective June 3, 2024. Anika Therapeutics, Inc. reported in an 8-K filed May 8, 2024 that Michael Levitz resigned as Executive Vice President, Chief Financial Officer and Treasurer, effective May 2, 2024. The proxy statement of Anika Therapeutics, Inc. reports total compensation of $1,774,860 for Michael Levitz in fiscal 2024, including a base salary of $514,582. Disclosed compensation is on record for 7 fiscal years. Michael Levitz has spoken on 7 earnings calls across 1 company, most recently for Anika Therapeutics, Inc. on May 8, 2024.
“You acknowledge and agree that your resignations described in the above subsection (i) shall be effective as of June 3, 2024.”
“On May 8, 2024, Anika Therapeutics, Inc. (the “Company”) announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024 (the “Effective Date”), replacing Michael Levitz, who tendered his resignation on May 2, 2024”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
Start not stated–2024-05-02
-
Start not stated–2024-05-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Anika Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Cheryl Blanchard CEO, Board Member
- Stephen (Steve) Griffin CEO, Board Member
- Stephen D. Griffin CEO, CFO, Board Member
- Steve Griffin CEO, Board Member
- Cheryl R. Blanchard Chairman, Board Member
- Jeffery S. Thompson Chairman
- John B. Henneman, III Chairman, Board Member
- Stephen Griffin CFO
- Anne Nunes COO
- David B. Colleran General Counsel
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Anika Therapeutics, Inc. (ANIK) | Former EVP, Chief Financial Officer and Treasurer | $514,582 | $1,774,860 |
| 2023 | Anika Therapeutics, Inc. (ANIK) | Former EVP, Chief Financial Officer and Treasurer | $496,000 | $1,651,818 |
| 2022 | Anika Therapeutics, Inc. (ANIK) | Former EVP, Chief Financial Officer and Treasurer | $474,600 | $1,826,386 |
| 2021 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | $456,400 | $1,588,856 |
| 2020 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | $173,077 | $1,857,960 |
| 2019 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | — | — |
| 2018 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.